Compare 10X Genomics Inc (TXG) vs Global X Uranium ETF (URA) Price & Performance

10x Genomics (TXG) trades at $82.37, up 8.24% over 24 hours, with a bearish technical signal and mixed analyst sentiment. The company reported a net loss of $43.54M in 2025, but revenue grew to $642.82M, and it has beaten EPS estimates for three consecutive quarters. Recent news highlights strong demand for its Atera platform and a patent victory, though profitability remains a challenge.

The outlook is cautiously optimistic, with growth potential from new product launches and spatial biology demand, but risks include persistent losses, high valuation multiples, and competitive pressures. The consensus price target is $74.30, below the current price, suggesting limited near-term upside.

URA is trading at $38.58, down 3.38% today amid bearish technical signals. The ETF shows negative momentum with all 13 moving averages signaling sell. Recent news highlights nuclear energy's growth potential, including US-Saudi atomic deals and AI-driven power demand, though uranium miners face price volatility. The fund provides diversified exposure to uranium miners, utilities, and nuclear infrastructure companies.

Outlook remains cautiously optimistic given nuclear energy's structural growth drivers, but near-term pressure persists from uranium price fluctuations. Key risks include commodity volatility and regulatory uncertainty, while catalysts include government nuclear investments and AI power demand. The current technical weakness may present entry opportunities for long-term investors.